Dr. Zeidan on Subsequent MDS in Prostate Cancer Patients After Radiotherapy

Video

Amer Zeidan, MBBS, MHS, assistant professor of Medicine, Hematology, Yale Cancer Center, discusses a population-based study of subsequent myelodysplastic syndromes (MDS) in prostate cancer patients after radiotherapy.

Amer Zeidan, MBBS, MHS, assistant professor of Medicine, Hematology, Yale Cancer Center, discusses a population-based study of subsequent myelodysplastic syndromes (MDS) in prostate cancer patients after radiotherapy.

Zeidan says this analysis looked at nearly 32,000 patients aged 69-99 at diagnosis who underwent surgery. The analysis compared patients who then underwent radiotherapy to those who did not. The study showed that patients who underwent radiotherapy had a slight risk of developing therapy-related MDS and acute myeloid leukemia, Zeidan says.

Therefore, physicians need to have discussions with their patients before continuing to radiotherapy.

<<<

View more from the 2015 MDS Symposium

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Guenther Koehne, MD, PhD
Minesh Mehta, MD
Ruben Olivares, MD
Lori A. Leslie, MD, an expert on lymphoma
Lori A. Leslie, MD, an expert on lymphoma
Phillip J. Koo, MD
Daniel Spratt, MD